STOCK TITAN

Labcorp's Planned Spin-off, Fortrea, to Host 2023 Investor Day

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
conferences

BURLINGTON, N.C., June 5, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced Fortrea, the new company to be formed by the planned spin-off of Labcorp's Clinical Development and Commercialization Services business, will host its inaugural Investor Day on Tuesday, June 6, 2023, in New York City at 9 a.m. ET.

This event will review Fortrea's business, operational outlook, growth strategies, and financial highlights with presentations from management including Chairman & CEO Tom Pike and CFO Jill McConnell. The presentations will be followed by a Q&A session.

A live webcast of the event will be available through the Labcorp Investor Relations website. For additional information on the event, please contact Hima Inguva, Fortrea's Head of Investor Relations, at Hima.Inguva@fortrea.com.

Transaction Update
Following the completion of the spin-off, Fortrea's common stock will be listed on The Nasdaq Stock Market LLC under the ticker symbol "FTRE." Labcorp common shares will continue to trade on the New York Stock Exchange under the symbol "LH."

The planned spin-off remains on track to be completed in mid-2023, subject to the satisfaction of certain customary conditions, including, among others, the receipt of final approval by the Company's board of directors, the receipt of appropriate assurances regarding the tax-free nature of the separation, and the effectiveness of any required filings with the Securities and Exchange Commission. Until the spin-off is complete, Fortrea's products, services and offerings are still owned and operated by Labcorp. Learn more about Fortrea at Fortrea.com.

About Labcorp
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With more than 80,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14.9 billion in FY2022. Learn more about us at Labcorp.com or follow us on LinkedIn and Twitter @Labcorp

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorps-planned-spin-off-fortrea-to-host-2023-investor-day-301842187.html

SOURCE Labcorp

Laboratory Corporation of America Holdings

NYSE:LH

LH Rankings

LH Latest News

LH Stock Data

16.88B
83.67M
0.34%
98.27%
2.29%
Diagnostic Imaging Centers
Health Care and Social Assistance
Link
United States of America
BURLINGTON

About LH

recognized for our innovation, quality, and customer convenience, labcorp delivers timely, accurate results for improved patient care. with scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology, labcorp performs more than one million tests on approximately 400,000 samples each day. labcorp is a pioneer in applying advances in medicine and science to laboratory testing, with more than 35 years of experience in serving physicians and their patients. labcorp operates a sophisticated laboratory network, with corporate headquarters in burlington, nc, and more than 34,000 employees worldwide. our more than 220,000 clients include physician offices, hospitals, managed care organizations, and biotechnology and pharmaceutical companies. laboratory corporation of america holdings is listed on the new york stock exchange (nyse) under ticker symbol lh.